This strategic partnership pairs two unique disruptors within the aesthetics and skincare industries, both focused on providing patients with high-quality results. With shared values and visions for business growth and an expanding footprint, the collaboration aligns two game-changing brands to offer more accessible solutions to aesthetic patients and providers nationwide.
For more than two decades, Revision Skincare® has been at the forefront of physician-dispensed brands. From pioneering the use of peptides to developing proprietary technologies and conducting novel ingredient research, this professional skincare brand creates clinically validated, high-potency products that protect, treat, and enhance the skin.
As another company invested in optimal patient health,
“We know that
Through the partnership, Revision Skincare® and
“We are thrilled to partner with Revision Skincare®. Their strong history of innovation and passion for skin health aligns with our core directive around ocular medical aesthetics,” said
Revision Skincare® and
About Revision Skincare®
Revision Skincare® is an industry leader in developing clinically-validated, high potency, transformative skincare products. Our unique formulation philosophy is an integrated approach that delivers maximum efficacy while maintaining long-term skin health. Based in
About
IMPORTANT SAFETY INFORMATION
INDICATION
UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.
WARNINGS AND PRECAUTIONS
- Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
- Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
- Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
- UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
- Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.
ADVERSE REACTIONS
Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ® were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.
DRUG INTERACTIONS
- Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as betablockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.
Contact: Revision Skincare PR
Company: M Booth
Tel: (212) 481-7000
Email: revisionpr@mbooth.com
Investor and Media Relations for
T: 212-452-2793
E: lwilson@insitecony.com
Source:
2022 GlobeNewswire, Inc., source